drugset / Trial / NCT00246064
The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
Timeline
- Start
- 2001-12
- Primary completion
- —
- Completion
- 2003-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Infliximab | Monoclonal antibody | 10 mg/kg | — |